8-K current report · filed Sep 22, 2026

Compass Therapeutics, Inc. (CMPX) 8-K Current Report: September 22, 2026

Item 7.01CMPX overview

Short answer

Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA regulatory feedback on tovecimig in biliary tract cancer, a potential second-line treatment path.

Compass Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA regulatory feedback on tovecimig in biliary tract cancer, a potential second-line treatment path
  • COMPANION-002 Phase 2/3 data planned for FDA discussion before a potential BLA submission
  • Complete COMPANION-002 dataset expected at a medical conference in 2026
  • Regulatory pathway remains contingent on FDA interactions, clinical data, and additional funding needs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Compass Therapeutics, Inc. 8-K filings

Get the next CMPX 8-K as it lands

Follow CMPX for push alerts, or ask the research agent what this filing means.